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Abstract Exhaled carbonmonoxide (CO), which has been found to be elevated in asthma, is generated primarily by
heme oxygenase1 (HO-1), an enzyme induced by oxidant stress and cytokines.The aim of this study was to assess the
distribution and expression of HO-1invarioushumanlungcells in acute and stable asthma.
Normal lung tissue biopsies (from 6 non-smoking subjects operated on for a lung tumour) and macrophages from
inducedsputum (from5healthycontrols,5 untreatedasthmatics,7 stabletreatedasthmatics and 5 asthmaticsrecovering
from exacerbation and being on systemic steroids) were investigated for HO-1by immunohistochemistry.The time re-
sponse of HO-1inductionwas examined in culturedmonocytes, which are knowntomaturate intomonocyte-derived
macrophagesinculture. Lungbiopsies showedprominentHO-1immunoreactivityonlyin alveolarmacrophages.Macro-
phages in the induced sputum of healthy controls showed no HO-1 immunoreactivity, with the exception of one case.
Moderate or intense HO-1immunoreactivity could be observed in alveolarmacrophages in 4/5 caseswith recent asth-
ma, and 2/7with stable asthma, but innone ofthepatients treatedwith systemiccorticosteroids for acute exacerbation.
Experimentswith cultured cells revealed that HO-1was induced byoxidantswithin the first 24 h, butthe inductionwas
reversed during the next 48 h. HO-1 is mainly expressed in alveolar macrophages of human lung.Macrophages of in-
duced sputum show prominent but transient HO-1 immunoreactivity, in untreated asthmatics, but not in asthmatics
treatedwith corticosteroids.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1283, available online at http://www.idealibrary.comon
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Carbon monoxide (CO) is elevated in the exhaled air of
asthma patients (1^4).This ¢nding is probably associated
with the up-regulation of heme oxygenase-1 (HO-1),
since previous studies have shown that total cellular CO
is generated primarily via heme degradation by HO-1.
(5^7). Immunoreactivity of HO-1has also been detected
in the bronchial biopsies (8) and bronchoalveolar lavage
£uid of asthma patients (1) .
The HO system consists of three proteins, an oxida-
tive stress-induced form of the enzyme, called HO-1,
and constitutive forms of the enzyme, all of which are
products of distinct genes (7,9). Due to its molecular
weight and rapid induction by heat and stress, HO-1hasReceived 5 November 2001, accepted in revised form12 December
2001.
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nase catalyses the rate-limiting step in the oxidative de-
gradation of heme to biliverdin, a reaction which also
releases CO and iron.
No systematic studies have been conducted on HO-1
expression or distribution in human lung tissue. A recent
study on bronchial biopsies of segmental airways ob-
tained by bronchoscopy showed a similar expression of
HO-1 in healthy controls and asthmatics (8). In our re-
cent study on patients with sarcoidosis and interstitial
pneumonia, however,HO-1was expressed only in alveo-
lar macrophages (10). Studies on rat lung have revealed
HO-1 immunoreactivity in bronchial epithelium and in-
£ammatory cells of the airways after hyperoxia and in al-
veolarmacrophages after hypoxia exposures (11,12).HO-
1 expression has also been detected in human mono-
cytes, where it is induced during erythrophagocytosis
and cell activation (13,14). It is also known that HO-1 is
stimulated not only by oxidants but also by endotoxin
and in£ammatory cytokines (5,11,15^18).
In this study, we ¢rst compared HO-1 expression in
various cell types of human lung and in small and large
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samples.These studies con¢rmed our recent ¢ndings on
HO-1expressionmainly in alveolarmacrophages.To bet-
ter understand the regulation of HO-1 in asthma, we
therefore assessed the expression of HO-1 in alveolar
macrophages obtainedby sputuminduction fromhealthy
subjects and asthma patients. The material included
samples from healthy non-smoking individuals, recently
diagnosed and untreated asthma patients, stable treated
asthmatics and patients in the acute phase of asthma
exacerbation under treatment. Furthermore, the time
response of HO-1 was assessed in human monocyte-
derivedmacrophages in culture.
METHODS
Lung tissue biopsies
The biopsy material of para⁄n-embedded tissues con-
sisted of lung tissue samples from 6 subjects (5 non-smo-
kers, one ex-smoker), all of whomhadbeen operated on
for a bronchial carcinoid tumour ormalignancy (lung car-
cinoma, sarcoma or metastasis). The control subjects
hadno other diseases andnomedication, their lung func-
tion was normal and the lung biopsies had been taken
from areas with normal-looking histology. The biopsies
were collected from the ¢les of the Department of
Pathology,Oulu University Hospital.
Frozen tissue samples
Frozen tissue samples were obtained from additional 5
patients operated on for a lung tumour. The samples
included central cartilage containing bronchus and, from
one patient, peripheral lung tissue.
Induced sputum
Patients and processing of samples
Induced sputum was obtained from 5 patients with
recently diagnosed untreated asthma, 7 patients with
stable asthma on inhaled corticosteroids and 5
asthmatics treated in hospital for asthma exacerbation
with systemic steroids for at least 3 days before sputum
sampling.The new and stable asthmatics were recruited
from the outpatient clinic of Oulu University Hospital
and the asthmatics with acute exacerbation from the
pulmonary ward of the same hospital. All the patients
were non-smokers. Forced expiratory £ow in 1sec
(FEV1) varied within 63^124% of the reference value in
the patients with asthma. The asthma diagnosis was
based on reversible airway disease, as shown by a posi-
tive histamine or methacholine challenge test, a X15%
increase in FEV1or PEF after the administration of an in-
haled bronchodilator, or daily PEF variabilityX20%.Thecontrols for the induced sputum group consisted
of 6 healthy non-smoking individuals with normal spiro-
metry ¢ndings and no history of asthma or other lung
diseases (Table1).
Twopatientswith asthma exacerbationproduced ade-
quate sputum after inhalation of nebulised bronchodila-
tors (salbutamol and ipratropium). In all other cases,
sputumwas inducedby inhalation of 5ml of 3% saline so-
lution using an ultrasonic nebuliser (Omron U1,Omron,
Germany). Both the healthy controls and the asthmatics
were given 0?2mg of salbutamol as dry powder inhala-
tion15minbefore the sputum induction.Peak expiratory
£ow (PEF) values were measured before and after the
induction to ensure the safetyof theprocedure.The sub-
jects were asked to cough during and after the inhala-
tion. Sputumwas collected in a clean plastic container. If
PEF decreased by more than 20% or subjective symp-
toms appeared, thepatientswere given 0?2mgof inhaled
salbutamol.
The sputumwas processedby themethod of Pizzichi-
ni andcolleagues (19). Sputumwhichwasmacroscopically
free of salivary contamination was selected and treated
with dithiotreitol (Sputolysin 10%, Calbiochem Corp.,
San Diego, CA, U.S.A.) and phosphate-bu¡ered saline.
Five hundred micro litres of the ¢ltered suspension was
used for the cell count and cytospin preparations.Only
adequate sampleswith less than 80% squamous epithelial
cell contamination from saliva (20) were accepted. In or-
der to study the expression ofHO-1inmacrophages, ad-
ditional cytospin preparations were ¢xed in acetone for
10min.
Immunohistochemistry
The histological slides were immunostained as follows.
The sections (4mm) were depara⁄nised in xylene and
dehydrated in graded ethanol.They were then incubated
with 30% hydrogen peroxide in absolute methanol to
consume the endogenous peroxidase.Background stain-
ing was minimised by treatment with 2% non-fat dry
milk.The primaryHO-1antibody (Transduction Labora-
tories, Lexington, KY, U.S.A.) was used in a dilution of
1:100, and the colourwas developedwith aminoethyl car-
bazole substrate solution (Zymed Laboratories). They
were then incubated with the secondary antibody fol-
lowed by HistostainTM-PLUS kit (Zymed Laboratories,
South San Francisco,CA,U.S.A.).The colour was devel-
oped with aminoethyl carbazole (AEC) substrate solu-
tion (Zymed Laboratories). The sections were
counterstainedwith a lighthaematoxylin stain.Thenega-
tive controls consisted of PBS at pH 7?2 and the mouse
serum isotype recommended by the manufacturer
(Zymed Laboratories).
Cytospin slideswere ¢xed in acetone for10min and in-
cubatedwith 8%hydrogenperoxide inwater to consume
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was minimised by treatment with 2% non-fat dry milk.
The same primary HO-1 antibody as for histological
slides was used in a dilution of1:100.
The frozen sections were cut into 4mm sections,
¢xed for 10min in cold acetone and air-dried overnight.
In order to consume endogenous peroxidase, the
slides were incubated in 30% hydrogen peroxide in
absolute methanol for 10min. Non-speci¢c staining was
blocked by incubating the slides in fetal calf serum.
Primary antibody for HO-1 was then applied (dilution
1:100) to the slides for 60min, followed by secondary
anti-mouse antibody for 30min, and the peroxidase^
antiperoxidase complex (Dako) for 30min. The
chromogen used was diaminobenzidine and the
slides were then lightly counterstained with hema-
toxylin.
HO-1 immunoreactivity was assessed semiquantita-
tively by two experienced lung pathologists indepen-
dently and the interobserver repeatability was excellent
(k=0?714). Immunoreactivity was graded as follows: 
negative, + weak, ++ moderate, +++ strong and ++++
very strong. All analyseswere conductedblindly without
information about the clinical characteristics of the
subjects.
Cell cultures and exposures
Monocytes were isolated from bu¡y coats (Finnish Red
Cross Helsinki, Finland) using a modi¢ed method de-
scribed by B˛ym (21).The bu¡y coats were diluted with
phosphate-bu¡ered saline (PBS), and the cell suspension
was layered over Ficoll-Paque (Pharmacia, Biotech AB,
Uppsala, Sweden) and centrifuged. Mononuclear cells
were collected at the interface, washed with PBS and
suspended in RPMI-1640 medium (Gibco Europe, Paisley,
U.K.) supplementedwith L-glutamine (Gibco), penicillin^
streptomycin (Gibco) and 20% human serum (Finnish
Red Cross). After isolation, the cells were incubated in
collagen-coated (Vitrogen, Collagen-Corporation, Palo
Alto,CA,U.S.A.) Petri dishes for1h at 371C. After incu-
bation, non-adherent cells were removed by washing
with PBS. Adherentmonocytes were cultured under 5%
CO2 at 371C for up to 72h which has been shown to in-
duce maturation of monocytes into monocyte-derived
macrophages. The monocytes were exposed to formy-
lated peptide fMLP (107M) (Sigma) or 100 and 500mM
H2O2 for 24 or 72h. FMLP is known to cause a respira-
tory burst of monocytes and macrophages, thereby
mimicking oxidative stress in vivo.
Western blotting
The cell pellets were mixed with the electrophoresis
sample bu¡er and boiled for 5min at 951C.The proteinconcentration of the samples was measured using the
Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA),
and 75mg of the cell protein was applied to 12% sodium
dodecyl sulphate-polyacrylamide gels. The gels were
electrophoresed for 1?5h (90V) at room temperature,
and the proteinwas transferred (45min,100V) ontoHy-
bond ECL nitrocellulose membranes (Amersham, Ar-
lington Hights, IL, U.S.A.) in a Mini-PROTEAN II Cell
(Bio-Rad).The blottedmembranes were incubated with
mouse antibody to HO-1 (diluted 1:250) followed by
treatment with anti-mouse secondary antibody (diluted
1:2000) conjugated to horseradish peroxidase (Amer-
sham).The reactivity was detected by an enhanced che-
miluminescence system (ECL, Amersham), and the
luminol excitationwas imaged on X-ray ¢lm.
The study protocol was accepted by the ethical com-
mittee of the University of Oulu and Oulu University
Hospital.
Statistical analysis
The statistical analyses were performed with SPSS for
Windows software (SPSS, Chicago, IL, USA).The signi¢-
cance of the associations was determined using Fisher’s
exact probability test designed for small sample groups.
P-values of less than 0?05 were considered statistically
signi¢cant.
RESULTS
Distribution and expression of HO-1in the
lung
The immunohistochemical reactivity of lung tissue was
investigated in 6 non-smoking individuals with normal
lunghistology.With the exception of one case, all control
lung biopsies showed strong HO-1 immunoreactivity in
alveolarmacrophages [Fig.1(c),Table 2].One biopsy from
a subject with a carcinoid tumour showed no HO-1 im-
munoreactivity in any cells of the biopsy.Given the fact
that HO-1 may show di¡erent expression patterns in
the large and small airways, we also assessed HO-1 im-
munoreactivity in the large, cartilage-containing air-
ways. However, even these samples were negative for
HO-1immunoreactivity.
Frozen lung samples from additional 5 patients were
assessed for HO-1 immunoreactivity. These results
showed no HO-1 reactivity in bronchial epithelium,
but alveolar macrophages showed positive immuno-
reactivity.
Induced sputum
Macrophages in the induced sputumof non-smoking con-
trols, with the exception of one case, showed no HO-1
FIG. 1. Hemeoxygenase-1expressioninalveolarmacrophages
in induced sputum [FIG1 (a and b) and in lung biopsies [Fig.1(c)].
Fig.1(a) shows aninduced sputum sample from a healthycontrol,
(b) a sample from a newly diagnosed asthmatic without anti-in-
£ammatory treatment, and (c) alungbiopsy fromanon-smoking
patient.
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tum, HO-1 immunoreactivity appeared to be present
more often in themacrophages of new asthmatics with-
out inhaled anti-in£ammatory therapy (4/5) than in cases
with stable asthma and inhaled anti-in£ammatory ther-
apy (2/7) (P=0?027, Fisher’s exact probability test) [Table
1and Fig.1(b)]. No HO-1 immunoreactivity could be de-
tected in the sputum of asthmatics recovering from
acute exacerbation who had been on systemic corticos-
teroid therapy for at least 3 days (P=0?023, Fisher’s exact
probability test).Cell cultures
The timeresponse ofHO-1inductionwas investigated in
culturedmonocytes, which are known to maturate into
macrophage-like cells in culture (22).Monocytes showed
scant expression of HO-1, which was enhanced by
500mMH2O2 and fMLPwithin the ¢rst 24h of exposure.
The inductionwas, however, only transient, since no ele-
vated HO-1 expression could be detected after 72h of
exposure anymore (Fig. 2).
DISCUSSION
The present study shows that HO-1 is expressed
in alveolar macrophages of human lung. It also
appears that oxidant stress causes a rapid but transient
induction of this enzyme in in£ammatory cells in vitro.
These results are in line with the expression levels of
HO-1 in vivo, since the present patient samples also
showed a tendency towards higher HO-1 reactivity in
the alveolar macrophages of untreated asthmatics
but not in subjects with stable disease or after 72h of
treatment.
Tissue specimens obtained from surgical operations of
non-smokers showed that HO-1 is expressed mainly in
alveolar macrophages. This result does not exclude the
possibility that small amounts of this enzyme could also
be expressed in other cells of human lung since immuno-
histochemistry may not be sensitive enough to detect
minor amounts of the enzymeprotein.Our present ¢nd-
ings are in agreement with our recent study on para⁄n-
embedded biopsies of sarcoidosis and interstitial pneu-
monias (10), which showed that HO-1 is expressed in
macrophages. There is one recent study on bronchial
biopsies obtained by bronchoscopy that investigated
HO-1immunoreactivity from frozen samples of segmen-
tal bronchial epithelium. In that study, similar positive
HO-1 immunoreactivity was detected in the epithelium
of healthy controls and asthmatic patients (8). In view of
inducibility of HO-1, however, bronchoscopy may cause
induction of this enzyme both in healthy subjects and in
asthmatics, and inductionmay also occur in healthy lung
during surgery. In our study, additional stainings were
alsomade on frozen lung biopsies, and even these results
revealed immunoreactivity only in macrophages. Di¡er-
ent levels of the bronchial tree may also show variable
HO-1 immunoreactivity, but based on our ¢ndings, the
large airways did not express HO-1, either. Thus,
these additional studies did not change the overall con-
clusion that alveolar macrophages represent the cell po-
pulation mainly responsible for HO-1 expression in
human lung.
Degradation of heme by HO-1 generates CO, and
exhaled CO has been suggested to be a sensitivemarker
of in£ammation in asthma (1,9, 23). The exhaled CO
concentration has, however, been shown to be higher in
TABLE 1. HO-1reactivity (0++++) in induced sputumof healthy controls, new untreated asthmatics, stable asthmatics on
anti^in£ammatory treatment and asthmatics after the treatmentof acute asthma exacerbation
Age Sex % of HO-1positivemacrophages Intensityof HO-1positivity*
Healthycontrols (group1)
32 M 0 
28 M 0 
56 M 0 
51 M 0 
22 F 0 
38 M 10 ++
Newasthma, no antiin£ammatory treatment (group 2)
50 F 40 +++
39 F 0 
21 F 5 +
44 F 10 ++
36 M 5 +
Stable asthma, inhaled corticosteroid therapy (group 3)
55 F 0 
49 M 5 ++
25 F 0 
48 F 0 
53 M 0 
46 F 0 
56 M 5 +
Asthma exacerbation, systemic corticosteroid therapy (group 4)
68 M 0 
45 F 0 
69 F 0 
55 F 0 
53 F 0 
*Heme oxygenase-1 immunoreactivity was graded as follows:  negative, + weak, ++ moderate, +++ strong and ++++
very strong.
According to Fisher’s exactprobability testthe following statistically signi¢cant associationswere found: group 2 vsgroups 3^4:
P=0?027; group 2 vsgroup 4:P=0?023.
FIG 2. Western blotting showing transiently elevated expres-
sion of HO-1 in monocytes exposed to 100 and 500 mMH2O2
and to fMLP (107M) for 24 and 72 h.
422 RESPIRATORYMEDICINEatopic subjects than in non-atopic individuals (24)
and similarly elevated in allergic rhinitis without asthma
(25). Exhaled CO is also elevated in respiratory
infections (23, 26) and smokers (27), which makes the
interpretations of exhaled CO in asthma even more
di⁄cult.Thepurpose of this study was not to investigateCO, but in agreement with the results on exhaled
CO, our study showed HO-1 to be up-regulated in the
alveolar macrophages of non-treated asthmatics, the
immunoreactivity of HO-1also being higher in untreated
than treated subjects with stable asthma. This is
also consistent with the rapid inducibility of this enzyme
and with the results on cultured monocytes showing
transient up-regulation of HO-1 in oxidant-exposed
cells.
In conclusion, our study shows that HO-1 is induced
especially in the alveolar macrophages of human lung and
that alveolarmacrophages areprobably themost important
cell type to explain high CO in the exhaled air of asthma
patients. Heme oxygenase may play a role in the acute
in£ammation of human lung, but due to its rapid induction
by oxidants, cytokines, infections and cigarette smoke, the
speci¢city of HO-1 in the di¡erential diagnosis of asthma as
well as in the clinical follow up of asthmatics appears to be
modest.
TABLE 2. Clinical information ofthe patients and expression of heme oxygenase-1in lungbiopsies
Age Sex Smoking Diagnosis Alveolarmacrophages
% of HO-1positive cells Intensityof HO-1inmacrophages
53 f Non Carcinoma 80 ++
38 f Non Sarcoma 90 +++
71 f Non Metastasis 90 +++
30 m Non Carcinoid 30 ++
55 f Non Carcinoid 0 
68 m Ex Carcinoma 5 ++++
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